Concepedia

Intratumoral expression levels of <i>PD-L1</i>, <i>GZMA</i>, and <i>HLA-A</i> along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma

Hiroyuki Inoue, Jae‐Hyun Park, Kazuma Kiyotani, Makda Zewde, Azusa Miyashita, Masatoshi Jinnin, Yukiko Kiniwa, Ryuhei Okuyama, Ryota Tanaka, Yasuhiro Fujisawa,

OncoImmunology · 2016 · 130 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

expression may respond preferentially to nivolumab treatment, which can enhance Th1-skewed cellular immunity with oligoclonal expansion of TILs.

References

21

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

, , +17

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

, , +17

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations

, , +17

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text

, , +14